MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance

0
24
Scientists investigated the roles of IRF4 and MYC in this context. Using bone marrow aspirates from patients with immunomodulatory drugs naïve or refractory multiple myeloma, they examined IKZF1/3 protein levels and IRF4/MYC gene expression following ex vivo pomalidomide treatment via flow cytometry and qPCR.
[Clinical Cancer Research]
Abstract